Evidence map›Paper›PMID 15016844›Full record

ArticleJournal of virology2004

Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load.

Agatha Masemola, Tumelo Mashishi, Greg Khoury, Phineas Mohube, Pauline Mokgotho, Efthyia Vardas, Mark Colvin, Lynn Zijenah, David Katzenstein, Rosemary Musonda and 9 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00006298 (Virological and Immunological Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa), which is not on this map. Cited by 121 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00006298 completednot on this map

Virological and Immunological Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa

TypeobservationalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrolled125ConditionsHIV Infections, HIV Seronegativity
3 · Its place in the literature

Who cites it

121 citing papers in PubMed, 1 synthesis or guideline pooled it, 214 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Antigenic competition in CD4Science translational medicine · 2019
    Trial
  5. HLA-B*14:02-Restricted Env-Specific CD8Journal of virology · 2017
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

61 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 7 countries.

Agatha MasemolaNational Institute for Communicable Diseases, Johannesburg, South Africa.
Tumelo Mashishi
Greg Khoury
Phineas Mohube
Pauline Mokgotho
Efthyia Vardas
Mark Colvin
Lynn Zijenah
David Katzenstein
Rosemary Musonda
Susan Allen
Newton Kumwenda
Taha Taha
Glenda Gray
James McIntyre
Salim Abdool Karim
Haynes W Sheppard
Clive M Gray
HIVNET 028 Study Team
National Center for Communicable Diseases · MNBlantyre Institute for Community Ophthalmology · MWNational HIV/AIDS/STI/TB Council · ZMPerinatal HIV Research Unit · ZACalifornia Department of Public Health · USMRC Clinical Trials Unit at UCL · GBNational Institute for Communicable DiseasesStanford Medicine · USUniversity of KwaZulu-Natal · ZAUniversity of the Witwatersrand · ZAUniversity of Zimbabwe · ZW

Funding

CENTRAL LAB FOR AIDS/HIV VACCINE EFFICACY TRIALSN01AI045202 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI SHEPPARD, HAYNES W · 1994 to 2000
$0k
NIAID NIH HHS N01-AI-45202
6 · The paper itself

Abstract

An understanding of the relationship between the breadth and magnitude of T-cell epitope responses and viral loads is important for the design of effective vaccines. For this study, we screened a cohort of 46 subtype C human immunodeficiency virus type 1 (HIV-1)-infected individuals for T-cell responses against a panel of peptides corresponding to the complete subtype C genome. We used a gamma interferon ELISPOT assay to explore the hypothesis that patterns of T-cell responses across the expressed HIV-1 genome correlate with viral control. The estimated median time from seroconversion to response for the cohort was 13 months, and the order of cumulative T-cell responses against HIV proteins was as follows: Nef > Gag > Pol > Env > Vif > Rev > Vpr > Tat > Vpu. Nef was the most intensely targeted protein, with 97.5% of the epitopes being clustered within 119 amino acids, constituting almost one-third of the responses across the expressed genome. The second most targeted region was p24, comprising 17% of the responses. There was no correlation between viral load and the breadth of responses, but there was a weak positive correlation (r = 0.297; P = 0.034) between viral load and the total magnitude of responses, implying that the magnitude of T-cell recognition did not contribute to viral control. When hierarchical patterns of recognition were correlated with the viral load, preferential targeting of Gag was significantly (r = 0.445; P = 0.0025) associated with viral control. These data suggest that preferential targeting of Gag epitopes, rather than the breadth or magnitude of the response across the genome, may be an important marker of immune efficacy. These data have significance for the design of vaccines and for interpretation of vaccine-induced responses.

Indexed as

Viral LoadAmino Acid SequenceCD8-Positive T-LymphocytesEpitopesHIV-1HIV AntigensHIV InfectionsHumansMolecular Sequence DataViremiaEpitopesHIV Antigens

Identifiers

PMID15016844
PMCPMC371059
OpenAlexW2112341438

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.